GlaxoSmithKline (GSK) has made Singapore the site of its new Asian headquarters that is scheduled to open in 2017 and will also house some staff from the US and UK.

[17] This highlights an unmet need for effective treatments for myelofibrosis patients with anaemia. [17] Dr. Stephanie Ambrose, GSK Singapore Medical Director, said: "We note that myelofibrosis is a ...

British pharmaceutical giant GSK has not met required ethical and regulatory standards in its marketing and prescription ...

GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy, tipped as one of its major launches for 2025 and a rival to Pfizer's first-to-market Penbraya. The shot protects ...

GSK’s vaccine portfolio. GSK’s portfolio of more than 20 marketed vaccines, one of the industry’s broadest, protects people against diseases such as meningitis, shingles, polio, measles ...

GSK and Pfizer said in the filing that they would dismiss the case with prejudice, which means it cannot be refiled. Spokespeople for the companies did not immediately respond to requests for ...

Singapore, and Hong Kong. In November 2023, the company reported positive headline outcomes from the Phase III DREAMM-7 head-to-head clinical trial of Blenrep for MM. "GSK reports positive ...